Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non‐small cell lung cancer patients at a lung cancer center in China

摘要

IBM Watson for Oncology (WFO) provides physicians with evidence‐based treatment options. This study was designed to explore the concordance of the suggested therapeutic regimen for advanced non‐small cell lung (NSCLC) cancer patients between the updated version of WFO and physicians in our department, in order to reflect the differences of cancer treatment between China and the United States.